Loading
KLF4 (Krueppel-like factor 4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Hepatocellular carcinoma, Skin cancer and 3 more.
Transcription factor; can act both as activator and as repressor. Binds the 5'-CACCC-3' core sequence. Binds to the promoter region of its own gene and can activate its own transcription.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 1.00, animal model 0.47, genetic association 0.57, somatic mutation 0.82). IntOGen calls it a driver in 5 cohorts (3 activating, 1 loss-of-function), covering Acute Lymphoblastic Leukaemia, Invasive Breast Carcinoma, Hepatocellular Carcinoma.
In plain words · KLF4 (Krueppel-like factor 4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Hepatocellular carcinoma, Skin cancer and 3 more.
KLF4 (Krueppel-like factor 4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Hepatocellular carcinoma, Skin cancer and 3 more.
Transcription factor; can act both as activator and as repressor. Binds the 5'-CACCC-3' core sequence.
No product in this corpus aims at KLF4 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA KLF4: RNA tissue enhanced (skin 1 186 nTPM); high antibody staining in 13 normal tissues; highest cancer staining head and neck cancer (2 of 4 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Hepatocellular carcinoma, Skin cancer (all types), Prostate cancer, Leukaemia); Open Targets associates it with 3 specific cancer types at or above 0.5 (breast carcinoma, cutaneous melanoma, prostate carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O43474; CIViC gene KLF4; IntOGen KLF4; Human Protein Atlas KLF4 tissue; Open Targets ENSG00000136826 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Garrett-Sinha L.A. et al, 1996. Source.
Sources: HGNC HGNC:6348 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O43474 (protein name, function text, keywords and locations (REST API)); CIViC gene KLF4 (1 evidence items, 0 assertions, 1 variants; diseases: (GraphQL API, CC0)); Open Targets ENSG00000136826 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: prostate cancer 0.50, melanoma 0.51, skin cancer 0.51, breast cancer 0.56 (GraphQL API, CC0)); IntOGen KLF4 (driver in 5 cohorts (Act 3, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcription factor; can act both as activator and as repressor. Binds the 5'-CACCC-3' core sequence. Binds to the promoter region of its own gene and can activate its own transcription. Regulates the expression of key transcription factors during embryonic development. Plays an important role in maintaining embryonic stem cells, and in preventing their differentiation. Required for establishing the barrier function of the skin and for postnatal maturation and maintenance of the ocular surface. Location: Nucleus; Cytoplasm (UniProt). Locus 9q31.2 (HGNC).
RNA: tissue enhanced (skin 1 186 nTPM), detected in many normal tissues.
Medium: Bone marrow, Placenta, Soft tissue, Tonsil.
Medium only: breast cancer, cervical cancer, lung cancer, melanoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KLF4" OR ABSTRACT:"KLF4" OR TITLE:"KLF transcription factor 4" OR ABSTRACT:"KLF transcription factor 4" OR TITLE:"Krueppel-like factor 4" OR ABSTRACT:"Krueppel-like factor 4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KLF4, not a curated reading list.